GEROLDI, DIEGO
 Distribuzione geografica
Continente #
NA - Nord America 1.964
EU - Europa 1.535
AS - Asia 1.035
OC - Oceania 4
AF - Africa 1
SA - Sud America 1
Totale 4.540
Nazione #
US - Stati Uniti d'America 1.954
CN - Cina 912
IE - Irlanda 460
UA - Ucraina 297
FI - Finlandia 241
DE - Germania 174
GB - Regno Unito 102
SG - Singapore 102
SE - Svezia 90
IT - Italia 86
FR - Francia 33
BE - Belgio 26
CA - Canada 9
NL - Olanda 9
JP - Giappone 8
IN - India 6
AU - Australia 4
CZ - Repubblica Ceca 3
PL - Polonia 3
RU - Federazione Russa 3
ID - Indonesia 2
NO - Norvegia 2
TR - Turchia 2
CR - Costa Rica 1
EC - Ecuador 1
ES - Italia 1
HU - Ungheria 1
IR - Iran 1
LT - Lituania 1
LV - Lettonia 1
MU - Mauritius 1
MY - Malesia 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
Totale 4.540
Città #
Dublin 460
Chandler 457
Jacksonville 337
Nanjing 272
Boardman 124
Ann Arbor 116
Beijing 110
Nanchang 104
Helsinki 96
Ashburn 95
Princeton 80
Singapore 74
Lawrence 73
Hebei 70
Shenyang 69
Medford 66
Changsha 63
Jiaxing 54
Wilmington 49
Tianjin 39
Hangzhou 37
Shanghai 35
New York 33
Woodbridge 29
Brussels 26
Milan 22
Verona 22
Norwalk 18
Seattle 17
Los Angeles 15
Des Moines 12
Piscataway 12
Auburn Hills 10
Fairfield 10
Pavia 10
Dallas 7
Toronto 7
Washington 7
Jinan 6
Taizhou 6
Kunming 5
Munich 5
Ningbo 5
Tokyo 5
Zhengzhou 5
Berlin 4
Hanover 4
Changchun 3
Frankfurt am Main 3
Ichibancho 3
Lanzhou 3
Naples 3
Orange 3
Brno 2
Canberra 2
Falkenstein 2
Groningen 2
Gunzenhausen 2
Houston 2
Lincoln 2
Oslo 2
Ottawa 2
Portland 2
San Francisco 2
Torun 2
Aberdare 1
Almere Stad 1
Amsterdam 1
Ardabil 1
Bloomfield 1
Borås 1
Bovisio Masciago 1
Brescia 1
Busto Arsizio 1
Crotone 1
Delray Beach 1
Fuzhou 1
Gdansk 1
Guayaquil 1
Indianapolis 1
Islamabad 1
Jakarta 1
Jinhua 1
Kuala Lumpur 1
Logan 1
Melbourne 1
Modena 1
New Haven 1
Paris 1
Perugia 1
Phoenix 1
Pomezia 1
Prague 1
Pune 1
Redwood City 1
Reghin 1
Riga 1
San José 1
Sopron 1
Springfield 1
Totale 3.259
Nome #
Decreased NT-3 plasma levels and platelet serotonin content in patients with hypochondriasis 98
Plasma eotaxin concentrations are associated with angiographic severity of coronary artery disease 96
Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation. 93
Relationship between plasma levels of soluble receptor for advanced glycation end products (sRAGE) and coronary artery disease 88
Significato prognostico dei livelli plasmatici di osteopontina in pazienti con angina pectoris stabile 86
Diabetes mellitus and silent myocardial ischemia in patients with coronary artery disease: comparison between patients with and without simptoms during provocative test. 84
Relationship between apolipoprotein(a) size polimorphism and coronary heart disease in overweight subjects 83
RAGE : a central player in nondiabetic vascular disease 83
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men 80
La chemochina regolatoria eotaxina-3 quale nuovo fattore predittivo di outcome cardiovascolare in pazienti con angina pectoris stabile 78
Apo(a) isoforms: a genetic marker for progression of coronary atherosclerosis. 78
Absence of Kir6.1/KCNJ8 mutations in Italian patients with abnormal coronary vasomotion 77
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension 76
Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes 76
Approccio genetico-clinico alla cardiopatia ischemica: analisi di 14 casi familiari. 76
The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin:contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. 74
A novel Val734Ile variant in the ABCC9 gene associated with myocardial infarction 74
The regulatory chemokine eotaxin-3 is a novel predictor of cardiovascular outcome in patients with coronary artery disease 74
374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis 74
Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects 74
Analisi mutazionale di Kir6.1/KCNJ8 in pazienti con angina vasospastica 73
Matrix metalloproteinase 2 may be a marker of microangiopathy compared to metalloproteinase 9 in children and adolescents with type 1 diabetes mellitus: A 5 year follow-up study 73
Raised plasma nerve growth factor levels associated with early-stage romantic love 72
Disfunzione erettile come predittore di eventi cardiovascolari maggiori in diabetici con coronaropatia silente angiograficamente documentata 71
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women 70
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 70
Circulating levels of osteopontin predicts future cardiac events in patients with chronic stable angina 69
Forma solubile del recettore dei prodotti finali di glicazione avanzata (sRAGE) ed aterosclerosi coronarica 69
Functional proteomics of energy-linked enzymes in lymphocytes after stroke. 69
Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension 68
QT interval duration in apparently healthy men is associated with depression-related personality trait neuroticism 68
High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans 64
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease 64
Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients 63
Cerebral ischemia and peripheral energy dysfunction in lymphocytes 63
Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. 63
Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target 62
The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. 62
Circulating levels of soluble receptor for advanced glycation end products in neurodegenerative and vascular dementia 61
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 59
Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism. 59
ATPases enzyme activities during ageing in different types of somatic and synaptic plasma membranes from rat frontal cerebral cortex 58
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 58
Enzyme activities in perikaryal and synaptic mitochondrial fractions from rat hippocampus during development 57
Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease 57
Action of piracetam and clonidine on different mitochondrial populations from hippocampus 57
Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. 57
Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. 56
Matrix metalloproteinase 2 and 9 evaluation in patients with or without diabetes during acute coronary syndrome and after the acute event 56
Matrix metalloproteinase 2 may be a marker of microangiopathy compared to metalloproteinase 9 in children and adolescents with type 1 diabetes mellitus: a 5-year follow-up study 56
Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk 55
Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease 54
High Lp(a) levels and atherogenic isoforms in patients with acute coronary sindrome 53
Fenotipi di apolipoproteina(a) come indicatori di suscettibilità genetica per rischio cardiovascolare in medicina del lavoro 53
Factors involved in drug interference on enzyme activities of three mitochondrial populations from rat hippocampus 52
The apolipoprotein(a) size polymorphism is assocated with Alzheimer's disease and vascular dementia 51
Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus 51
Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients 50
Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects 48
Peripheral energy dysfunction in cerebral ischemia: focus on lymphocytes. 48
Prevalenza di elevati livelli di Lp(a) e di isoforme aterogene in un gruppo di pazienti del Nord Italia con sindrome coronarica acuta 47
Genetic loading on human loving styles 47
Energy metabolism of lymphocytes from acute stroke patients 45
Valutazione delle metalloproteasi 2 e 9 in pazienti con o senza diabete durante sindrome coronarica acuta e dopo evento acuto 44
Prognostic significance of plasma osteopontin levels in patients with chronic stable angina 44
Increased Plasma Aldosterone Concentrations in Patients with Clinical Depression 44
Relationship between platelet serotonin content and rejections of unfair offers in the ultimatum game. 43
Lymphocytes bioenergetics after stroke: a functional proteomic study 41
Restenosis after intracoronary stent placement: can apolipoprotein(a) polymorphism play a role? 40
Energy metabolism of mitochondria after ischemia and recovery times during aging and peripheral energy dysfunction in stroke patients: focus on lymphocytes 38
Mitochondrial Energy Metabolism of Brain and Lymphocytes after Ischemia and Recovery during Aging 33
Mitochondrial Energy Metabolism of Brain and Lymphocytes after Ischemia and Recovery during Aging 30
Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes 28
Totale 4.565
Categoria #
all - tutte 17.674
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.674


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020247 0 0 0 0 0 0 8 54 10 102 67 6
2020/2021500 57 45 20 54 3 73 7 71 15 74 66 15
2021/2022326 7 3 9 8 2 5 8 20 16 19 49 180
2022/20231.338 139 107 17 98 149 124 0 78 556 17 34 19
2023/2024424 77 85 11 26 34 95 4 37 3 13 19 20
2024/2025254 18 82 50 32 34 38 0 0 0 0 0 0
Totale 4.565